Resource Center

A randomized clinical trial of 178 veterans with posttraumatic stress disorder (PTSD) found that written exposure therapy (WET) had similar effects in reducing symptoms as the traditionally used prolonged exposure therapy (PE). Veterans received either five to seven sessions of WET or eight to fifteen sessions of the lengthier PE treatment, and were assessed at baseline, 10, 20, and 30 weeks after the initial treatment session. Improvements in symptom severity from baseline to all later assessments were similar among Veterans receiving WET and PE, with the largest difference favoring WET at 10 weeks. Furthermore, veterans receiving WET were less likely to stop treatment, suggesting it may reduce barriers to engagement associated with other interventions. To learn more, read the article in JAMA.

The U.S. Federal Drug Administration (FDA) has approved the first oral medication, Zurzuvae , for the treatment of postpartum depression (PPD). Onset of PPD can occur during the late stages of pregnancy or after childbirth. Previously, PDD medication was only available via IV injection from a health care provider. The effectiveness of Zurzuvae was tested against placebos in two distinct, randomized, double-blind studies for a period of 14 days. In both studies, patients taking Zurzuvae showed a more significant decrease in depressive symptoms at study conclusion, and four weeks after, compared to placebo groups. The approval goes a long way in improving accessibility of PPD treatment for the many individuals the condition affects each year. To learn more, read the news release from the FDA.

Patients with bipolar disorder experience cyclic episodes of mania and depression which makes symptom management challenging. Common treatment practices include antidepressants and mood stabilizers or antipsychotics. An international clinical trial study of 177 patients with Bipolar I in remission from a depressive episode were randomly assigned to continue antidepressant use for 52 weeks or taper antidepressant use after six weeks and begin taking a placebo at eight weeks. Patients continuing antidepressant use were significantly less likely to experience a depressive episode (17%) compared to those taking a placebo (40%). However, 12% experienced a manic episode compared to 6% in the placebo group. Further research is needed to better understand the maintenance of manic and depressive episodes in patients with bipolar disorder. To learn more, read the article in the New England Journal of Medicine.